High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...

A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. This is an ASCO ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Autonomic nerve invasion may be simple method of identifying which patients with intermediate-risk T3a prostate cancer who have negative surgical margins after radical prostatectomy are at increased ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

A new cohort study included 778 men with prostate cancer who had received either radiation or surgery within 1 year of diagnosis. Patients who lived in rural areas had nearly twice the rate of ...

Proton beam therapy continues to generate significant interest — and controversy — in prostate cancer. About 45 cancer centers in the US offer proton therapy to treat a variety of cancers, including ...

Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...